Novo Nordisk Parent Resubmits Catalent Deal Application to FTC

Novo Nordisk’s parent company, Novo Nordisk Foundation, has refiled its application to the U.S. Federal Trade Commission (FTC) seeking approval for its $16.5 billion acquisition of manufacturing subcontractor Catalent, a spokesperson announced on Monday.

The move comes after an earlier application submitted on March 4 was withdrawn following informal discussions with FTC staff. The new application was filed on April 2, as disclosed in a recent Catalent SEC filing dated April 3.

Last month, Novo Nordisk Foundation announced its intention to acquire Catalent to enhance production capabilities for its weight-loss drug Wegovy. As part of the agreement, three of Catalent’s fill-finish sites will be sold to Novo Nordisk for $11 billion post-acquisition.

When asked about the timeline for completing the deal, a spokesperson for Novo Nordisk declined to provide further details. However, the company confirmed that the resubmission of the application was intended to provide authorities with additional time for review.

Novo Nordisk had previously anticipated completing the acquisition by the end of 2024. However, given the recent developments, the timeline remains uncertain.

For further inquiries, Novo Nordisk Foundation can be contacted directly for comment on the reapplication process and any potential implications.

Related posts:

Novo Nordisk’s Controlling Shareholder Plans To Invest About $7 Billion a Year By 2030 Novo Nordisk to Invest $2.3 Billion in France for Production Expansion Novo Nordisk Completes The Acquisition Of Canada’s Inversago for $1bn Novo Nordisk, Eli Lilly, Boehringer Ingelheim Support Medicare Obesity Drug Coverage